Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia has identified a new lead compound for advancement in its alliance with GlaxoSmithKline, through its collaboration with the Center of Excellence for External Drug Discovery.
Subscribe to our email newsletter
This newly identified lead compound is the second from a program being evaluated as a potential treatment for respiratory disease. As a result of this identification, Pharmacopeia received a $500,000 milestone payment from GlaxoSmithKline (GSK).
Pharmacopeia is entitled to success-based milestone payments totaling up to $83 million per program and potentially double-digit royalties on the sales of any product commercialized by GSK under the multi-program alliance.
Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia may independently pursue them, subject to its obligations to GSK under the alliance. With the achievement of this milestone, Pharmacopeia has received $17 million from GSK in connection with the alliance.
Hugh Cowley, senior vice president of GSK and head of the CEEDD, said: “With the identification of this compound, our collaboration has now identified a total of four new leads. We are extremely pleased to see the rapid and impressive achievements of the team driving this successful collaboration.”